Latest Conference Articles

The gold standard for measuring treatment outcomes in multiple sclerosis (MS) is the randomized clinical trial (RCT). However, RCTs are often short-sighted and biased in their execution. Dr Maria Sormani, PhD, Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, addressed this problem in a lecture on immunomodulatory treatment of MS.

In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.

Clinical trials and treatment in multiple sclerosis (MS) place an unwelcome economic burden upon countries with MS prevalence. With rising costs and a growing interest in MS clinical trials from emerging countries, new studies are needed to evaluate the significance of these factors.

Fatigue and cognitive impairment are 2 of the most common health problems associated with multiple sclerosis (MS). Recent MS studies evaluate the nature of these 2 conditions not just as side effects of MS, but as chronic conditions with varying degrees of severity based on objective assessment and self-perception.

Barry Singer, MD, director, MS Center for Innovations in Care, St. Louis, MO, said that the Affordable Care Act could cause challenges in terms of coverage.

New disease-modifying drugs in multiple sclerosis (MS) show potential for improving quality-of-life (QoL) of patients with multiple sclerosis. The clinical benefits of dimethyl fumarate and PR-fampridine were discussed at a Biogen Idec-sponsored satellite symposium at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with.

Recent discussions of risk gene variation and pharmacogenitc studies were highlighted at a parallel session during the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Genome-Wide Association Studies (GWAS) have identified over 100 common risk variants in just over a quarter of observed heritability.

Predictors of long-term disability and treatment failure in multiple sclerosis were discussed at a platform presentation during the 29th Congress European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). In the first presentation discussed here, Marzia Romeo, MD, San Raffaele Hospital, Milan, Italy, shared findings from an observational study examining the viability of early prediction of long-term treatment failure in relapsing remitting multiple sclerosis (RRMS) patients treated with disease-modifying treatments (DMT).

At a satellite symposium during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, presenters focused upon the usage of disease-modifying treatments (DMT) in relapsing-remitting multiple sclerosis (RRMS).

Self-reporting among multiple sclerosis (MS) patients was the focus of 2 posters during a Quality of Life (QoL) poster session at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

During a Merck Serono-sponsored satellite symposium at the 29th Annual European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, presenters shared research regarding patient engagement in treatment management for multiple sclerosis (MS). The presentation focused primarily on the relationship between patients with MS (PwMS) and their treating physicians.

In the last two decades we've seen really an explosion of the treatments we have for multiple sclerosis (MS), said Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology.

Brenda Banwell, MD, Chief, Division of Neurology, Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, said that there are 3 areas of treatment associated with pediatric multiple sclerosis (MS).

In this video, Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute, professor and vice chair of clinical affairs, Department of Neurology, SUNY at Stony Brook, emphasized the need to establish biomarkers for the treatment of multiple sclerosis.

Highlights from American Diabetes Associations (ADA) which took place on June 21-25, 2013, in Chicago, IL, are available in a newsletter published by The American Journal of Managed Care.

Rodney Hayward, MD, and Sheldon Greenfield, MD, discussed the benefits of quality care measures and explored some of the remaining areas for improvement. Some groups advocate for the use of composite quality care measures that reflect treatment guidelines and suggest that the same targets not be applied to all patients.

Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with additional effects beyond prolonging the effect of incretins. Laurie Baggio, PhD, reviewed many of the studies showing the independent anti-inflammatory effects of these drugs, which may be explored for future indications. These effects may help scientists understand some of the mechanisms behind inflammation in the body, as explained by Julio Ayala, PhD. Finally, concerns about pancreatitis with DPP-4 inhibitors and GLP-1 agonists may be largely unfounded, as explained by Vanita Aroda, MD.

In this session, Robert Eckel, MD, discussed new and emerging therapies for obesity. New agents fill a therapeutic gap by allowing patients to achieve weight loss between 5% and 15% of body weight, leading to improved outcomes in patients with type 2 diabetes and metabolic disease.

Ronald J. Sigal, MD, MPH, a professor of medicine, cardiac sciences, kinesiology, and community health sciences at the University of Calgary in Canada, and a Health Senior Scholar at the Alberta Heritage Foundation for Medical Research, pulls from his experience to discuss the reality of the current expectations and goals for exercise and physical activity in the overweight or obese patient with diabetes, and offers his solutions.

Philip R. Schauer, MD, the director of the Bariatric and Metabolic Institute (BMI) at the Cleveland Clinic in Ohio contends that accountable care organizations (ACOs) need to recognize obesity as a legitimate disease that is the basis for many other serious conditions. He emphasizes that obesity certainly requires treatment, and surgery is an appropriate intervention for certain patients.

Carl Dean Benton, RPh, explains how pharmacists can contribute to improvements in patient care through counseling programs. With the provisions of the Affordable Care Act, many insurers may begin to recognize the benefits of pharmacist-driven counseling initiatives, and integrate these programs to help improve outcomes for patients with type 2 diabetes.

Todd Brusko, PhD, of the Todd M. Brusko Laboratory at the University of Florida College of Medicine, discussed how knowledge of regulatory T-cells has grown and improved, and noted that research has now entered a phase of harnessing the potential of our immune system through specific cell populations to combat root causes of type 1 diabetes (T1DM).

Allan Geliebter, PhD, the senior research scientist in the Department of Psychiatry at Columbia University and a professor of psychology at Touro College explains the roles of various hormones in appetite stimulation and suppression, and discusses how functional MRI of the brain may demonstrate a relationship between bariatric surgery in obese patients, neurological response, and hormone regulation.

Bernard Zinman, MD, the director of the Leadership Sinai Centre for Diabetes and the Sam and Judy Pencer Family Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto in Canada, discusses the new therapies, SGLT-2 inhibitors, that are now approved in the United States and European Union. These drug therapies have shown clinical benefits in both type 1 and type 2 diabetes, and may also improve cardiovascular outcomes for patients with type 2 diabetes

Jaakko Tuomilehto, MD, PhD, a professor of public health at the University of Helsinki in Finland provides global epidemiological data for T1DM and discusses the World Health Organization's Diabetes Mondiale (DiaMond) study. He compares the rates of incidences of T1DM among well-developed, high-income countries to low- and middle-income nations and takes note of the epidemiological trends.

In light of ongoing healthcare reform in the US, Sheldon Greenfield, MD, the executive co-director of the Health Policy Research Institute and Donald Bren Professor of Medicine at the University of California Irvine School of Medicine, shared his insights on the role of quality care measures in the management of diabetes, and weighed in on the advantages and disadvantages associated with implementing these tools.

Accounting for what is known about the association between diabetes and low testosterone in men, Rita Basu, MD, a professor of medicine at the Mayo Clinic in Rochester, MN provides her insights on the role of testosterone supplementation in men with diabetes, and notes how clinical and managed care perspectives are integrated in practice.

Cost-effectiveness analyses (CEAs) have real effects on therapeutic approaches for patients with type 2 diabetes mellitus (T2DM). Dr. Gilmer discusses how studies like the United Kingdom Prospective Diabetes Study (UKPDS) and the Diabetes Prevention Program (DPP) have affected how researchers and scientists evaluate the benefits of new treatments.

Sandeep Dhindsa, MD, an associate professor of medicine at the University of Buffalo School of Medicine and Biomedical Sciences discusses the relationship between diabetes and low testosterone in men, and also notes the significance of accounting for BMI and obesity.